# U.S. EPIDEMIOLOGICAL RESEARCH SINCE IMPLEMENTATION OF HIPAA: ISSUES AND IMPLICATIONS

Martha Linet, M.D.
President-Elect
American College of Epidemiology
November 20, 2003

### **Outline of Presentation**

- I. Early experience and problems
- II. Cross-cutting issues: impact on participation rates; financial and legal issues
- III. Ongoing assessment of impact of HIPAA
- IV. Possible remediation measures

### **Initial Reactions to HIPAA**

- Early days only 6 months has passed
- Reports are mixed
  - ongoing studies may be less influenced
  - industry may be less impacted
  - new studies encountering some difficulties
- Different and variable interpretation by IRBs and hospitals

### **Problem: Database Access Restricted**

- Prior to HIPAA: could identify
  - controls from Centers for Medicare and Medicaid Services (CMS, formerly HCFA) databases
  - subjects from hospital records
- Since implementation of HIPAA: access denied
  - to CMS databases for control selection
  - to hospital records without a waiver (IRBs variable in granting waivers)

# Problem: Variable Access to Medical Records of Individual Subjects

- Prior to HIPAA: universal simple release form generally accepted, but epidemiological studies impacted by
  - signed release effective for shorter intervals
  - increasing costs to obtain records
- Since implementation of HIPAA: variable access to records, notable complexity of release forms, and increased requirements for subjects to
  - designate specific record components for release
  - absolve hospitals from liabilities, responsibilities, damages and claims arising from release of record information
  - recognize hospital's right to deny or revoke a release

# **Problem: Increasing Length and Complexity of Consent Forms**

- Prior to HIPAA: consent forms
  - generally simpler and more standardized
  - fewer legal requirements
- Since implementation of HIPAA: forms include more institution-specific and/or expanded wording
  - increased requirements for witness, notarization, proof of kinship/power of attorney
  - copy of protocol; dates of treatment, expiration of authorization

# Problem: Expanded Disclosure of Confidential Data to More Entities

- Prior to HIPAA: access to confidential data restricted to investigators directly involved in research project
- Since implementation of HIPAA: expansion of entities (IRBs, funding agencies, adjunct investigators) to which confidential data from subjects can be disclosed

# **Decline in Participation**

- Factors that may cause decline in participation:
  - unwillingness of IRB to grant waiver ⇒ investigator can't identify eligible subjects
  - lack of access to medical records ⇒
    investigator can't confirm diagnosis, ascertain 'exposure'
  - length and complexity of consent form ⇒
     subject may not understand or object to one component
  - expanded disclosure of confidential information ⇒ subject may refuse participation

# Financial and Legal Impact

- Financial: increased costs from additional time for
  - designing forms and training staff in HIPAA requirements
  - preparing IRB packages
  - answering subject queries, obtaining agreement of hospitals to provide records
- Legal: some hospitals have expressed concern about
  - risk of federal audit ⇒ may preclude hospital IRB from granting waiver

# **Ongoing Assessment of Impact**

- Continue to Evaluate Experiences of Individual
   Investigators: goal is to identify patterns
- <u>Conduct Survey:</u> goal is to prepare and administer standardized data collection survey instrument when patterns have become apparent
- Communication with Members of Epidemiological
   Organizations: goal is to keep epidemiologists apprised of impact of HIPAA on research

### Possible Remediation Measures - I

#### **Problem**

- Database access
- Complexity of consent forms
- Too many parties given access to confidential information

#### **Potential Solution**

- Re-examine granting access
- Provide simplified template for universal record release
- Limit parties given access (no need for IRB or funding agencies to have access)

## Possible Remediation Measures - II

#### **Problem**

- Differential interpretation of HIPAA requirements
- Falling participation rates

Institutional unwillingness to grant waivers

#### **Potential Solution**

- Clearer communication of HIPAA requirements
- Education by DHHS of IRBs, hospitals, etc.
- DHHS should proactively reassure institutions